HYRIS is a platform that developed the smallest DNA analyzer available in the market for niche portable application. The company develops and markets a disruptive platform for mobile DNA analysis, including all hardware and software elements needed. It is already in the market with commercial sales to several top tier industrial and governmental clients in Europe and North America. Recently, Hyris has adapted its features to test for the presence of COVID-19 pathogens using World Health Organization compliant reagents.
Cross Border assisted Hyris to find partners funding a capital increase for the company’s growth, stimulating the interest of three international Venture Capital funds. Hyris was therefore able to choose Astanor Ventures as lead investor and obtain a greater commitment than initially expected for the round.
Cross Border prepared the fundraising documentation and assited Hyris in the due diligence and the negotiation of shareholders agreement and articles of association.